NASDAQ:SERA Sera Prognostics (SERA) Stock Price, News & Analysis $8.43 +0.40 (+4.98%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.80▼$8.5650-Day Range$5.29▼$9.9152-Week Range$1.52▼$12.35Volume123,377 shsAverage Volume217,756 shsMarket Capitalization$275.27 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Sera Prognostics alerts: Email Address Sera Prognostics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside67.4% Downside$2.75 Price TargetShort InterestHealthy3.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 4 Articles This WeekInsider TradingSelling Shares$572,627 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.94) to ($0.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.70 out of 5 starsMedical Sector872nd out of 936 stocksMedical Laboratories Industry18th out of 18 stocks 1.3 Analyst's Opinion Consensus RatingSera Prognostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSera Prognostics has only been the subject of 1 research reports in the past 90 days.Read more about Sera Prognostics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.34% of the float of Sera Prognostics has been sold short.Short Interest Ratio / Days to CoverSera Prognostics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sera Prognostics has recently increased by 147.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSera Prognostics does not currently pay a dividend.Dividend GrowthSera Prognostics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SERA. Previous Next 2.5 News and Social Media Coverage News SentimentSera Prognostics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sera Prognostics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Sera Prognostics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $572,627.00 in company stock.Percentage Held by Insiders15.80% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sera Prognostics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sera Prognostics are expected to grow in the coming year, from ($0.94) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sera Prognostics is -7.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sera Prognostics is -7.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSera Prognostics has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sera Prognostics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.I have uncovered a bombshell that changes everything… and threatens everything. About Sera Prognostics Stock (NASDAQ:SERA)Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Read More SERA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SERA Stock News HeadlinesJuly 25 at 8:30 AM | prnewswire.comSera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024July 9, 2024 | prnewswire.comSera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT TrialJuly 27, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 1, 2024 | prnewswire.comSERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTIONJune 16, 2024 | investorplace.com3 Stocks Under $10 With the Potential to Make You a MillionaireMay 28, 2024 | prnewswire.comSERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXESMay 12, 2024 | uk.investing.comSera Prognostics CFO sells shares worth over $63,000May 12, 2024 | investing.comSera Prognostics CEO sells shares worth over $115kJuly 27, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 10, 2024 | finance.yahoo.comSera Prognostics Inc Reports Q1 2024 Results: A Closer Look at Financials and Strategic MovesMay 10, 2024 | finance.yahoo.comSera Prognostics First Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.34 loss in 1Q 2023)May 9, 2024 | finance.yahoo.comSera Prognostics, Inc. (NASDAQ:SERA) Q1 2024 Earnings Call TranscriptMay 8, 2024 | investorplace.comSERA Stock Earnings: Sera Prognostics Beats EPS for Q1 2024May 8, 2024 | prnewswire.comSERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTSMay 8, 2024 | markets.businessinsider.comSera Prognostics A is about to announce its earnings — here's what Wall Street expectsApril 29, 2024 | prnewswire.comSera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024April 19, 2024 | morningstar.comSera Prognostics Inc Class AApril 16, 2024 | finance.yahoo.comEarlyDiagnostics, Inc. Co-CEO Gregory C. Critchfield, M.D. M.S., Receives Utah Governor's Medal for Science and TechnologySee More Headlines Receive SERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:SERA CUSIPN/A CIK1534969 Webwww.seraprognostics.com Phone801-990-0520FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$2.75 High Stock Price Target$2.75 Low Stock Price Target$2.75 Potential Upside/Downside-67.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,240,000.00 Net Margins-11,843.79% Pretax Margin-16,395.15% Return on Equity-46.35% Return on Assets-36.31% Debt Debt-to-Equity RatioN/A Current Ratio2.19 Quick Ratio2.19 Sales & Book Value Annual Sales$310,000.00 Price / Sales887.87 Cash FlowN/A Price / Cash FlowN/A Book Value$2.21 per share Price / Book3.81Miscellaneous Outstanding Shares32,650,000Free Float27,495,000Market Cap$275.24 million OptionableOptionable Beta1.05 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Evguenia Lindgardt M.B.A. (Age 50)President, CEO & Director Comp: $37.5kDr. Gregory C. Critchfield M.D. (Age 71)M.S., Executive Director Comp: $790.74kDr. Steven W. GravesCo-Founder and Co-Chairman of The Scientific Advisory BoardDr. M. Sean Esplin M.D.Co-Founder and Co-Chairman of Scientific Advisory BoardMr. Austin AertsChief Financial Officer??Dr. John J. Boniface Ph.D. (Age 62)Chief Scientific Officer Comp: $386.69kMr. Robert G. Harrison (Age 58)Chief Information Officer Comp: $384.18kMr. Benjamin G. Jackson J.D. (Age 45)General Counsel Comp: $410.75kDr. Paul Kearney Ph.D. (Age 56)Chief Data Officer More ExecutivesKey CompetitorsLucid DiagnosticsNASDAQ:LUCDCo-DiagnosticsNASDAQ:CODXTalis BiomedicalNASDAQ:TLISInnovAgeNASDAQ:INNVFulgent GeneticsNASDAQ:FLGTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 75,441 shares on 7/26/2024Ownership: 0.462%Twelve Points Wealth Management LLCBought 43,388 shares on 7/12/2024Ownership: 0.133%Sanders Morris Harris LLCBought 15,700 shares on 7/12/2024Ownership: 0.107%Zhenya LindgardtSold 26,867 sharesTotal: $217,891.37 ($8.11/share)Austin AertsSold 5,415 sharesTotal: $43,915.65 ($8.11/share)View All Insider TransactionsView All Institutional Transactions SERA Stock Analysis - Frequently Asked Questions How have SERA shares performed this year? Sera Prognostics' stock was trading at $5.98 at the beginning of the year. Since then, SERA stock has increased by 41.0% and is now trading at $8.43. View the best growth stocks for 2024 here. How were Sera Prognostics' earnings last quarter? Sera Prognostics, Inc. (NASDAQ:SERA) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.02. Sera Prognostics had a negative net margin of 11,843.79% and a negative trailing twelve-month return on equity of 46.35%. When did Sera Prognostics IPO? Sera Prognostics (SERA) raised $75 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 4,687,500 shares at $15.00-$17.00 per share. Who are Sera Prognostics' major shareholders? Sera Prognostics' top institutional shareholders include Bank of New York Mellon Corp (0.46%), Twelve Points Wealth Management LLC (0.13%) and Sanders Morris Harris LLC (0.11%). Insiders that own company stock include Zhenya Lindgardt, Austin Aerts, Paul Kearney, John J Boniface and Robert Gardner Harrison. View institutional ownership trends. How do I buy shares of Sera Prognostics? Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SERA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sera Prognostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
